A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee
Phase of Trial: Phase I/II
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Dexamethasone (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- Sponsors Taiwan Liposome Company
- 03 Jan 2017 According to a Taiwan Liposome Company media release, the observation period has lengthened to 24 weeks compared to the 12 week duration in this trial to determine the maximum duration of efficacy.
- 16 Dec 2016 Status changed from active, no longer recruiting to completed.
- 18 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Nov 2016.